Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TOP2A | P11388 | 3/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241091 | 0.83 | LMNA (0.63) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL5874071 | 0.83 | KEAP1 (0.46) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL22774208 | 0.83 | KEAP1 (0.46) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL28331885 | 0.83 | KDM4E (0.52) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL16469689 | 0.82 | LMNA (0.48) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL9288483 | 0.82 | LMNA (0.51) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL12665410 | 0.82 | LMNA (0.43) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| Fluoride SCHEMBL5144825 | 0.81 | LMNA (0.61) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL7230355 | 0.81 | LMNA (0.39) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 | |
| SCHEMBL5144832 | 0.80 | LMNA (0.60) | KEAP1NFE2L2LMNACYP2C9ATP6V1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991992-B1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9540399-B2 | Quinolone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-2776431-B1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-04 | — | — | EP | disclosed |
| EP-2991992-A1 | QUINOLONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160060276-A1 | QUINOLONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9079922-B2 | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-19 | — | — | US | disclosed |
| WO-2014178008-A1 | QUINOLONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2011037433-A2 | USE OF A QUINOLONE DERIVATIVE CONTAINING 7-(4-AMINOMETHYL-3-OXIME)PYRROLIDINE GROUP THAT IS CAPABLE OF INDUCING GRANULOCYTE COLONY STIMULATING FACTOR FOR TREATMENT OF NEUTROPENIA AND RECOVERY OF HEMATOPOIESIS | LG LIFE SCIENCES LTD. (KR) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060276-A1 | QUINOLONE DERIVATIVES | NQO2, QARS1, RECQL | KEAP1 1018/4885NFE2L2 1183/4885LMNA 1891/4885 |
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | OXA1L, PYM1, MRPL21 | KEAP1 2043/4885NFE2L2 3179/4885LMNA 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.